Seminars in 2013
David FitzGerald (NCI)
January 25, 2013 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Immunotoxin development for cancer treatment – future directions"
Mitchell Ho (NCI)
February 22, 2013 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Novel monoclonal antibodies targeting glypican-3 in liver cancer" (sponsored by NCI/CCR)
Seminars in 2012
Adrian Wiestner (NHLBI)
January 27, 2012 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Targeting CD20 in Chronic Lymphocytic Leukemia: ADCC, Complement, and Pharmakokinetics"
Hisataka Kobayashi (NCI)
February 24, 2012 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Photo-immunotherapy; a new highly selective cancer therapy with armed antibody based on photo-physics and chemistry"
Sarah K. Browne (NIAID)
March 23, 2012 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Immunodeficiency due to anti-IFN-γ autoantibodies: the roles of titer and avidity in determining biological function"
Weizao Chen (NCI Frederick National Lab)
April 27, 2012 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Engineered single antibody domains (eAds) and eAd-based multispecific fusion proteins as candidate therapeutics"
Viktor Roschke (Zyngenia, Inc.)
May 25, 2012 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Zybodies: multi-specific, multi-valent single-protein therapeutics"
Brad St. Croix (NCI Frederick National Lab)
June 22, 2012 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Development of Therapeutic Antibodies that Discriminate Pathological and Physiological Angiogenesis"
James N. Kochenderfer (NCI)
September 28, 2012 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Treatment of B-cell Malignancies with T cells Expressing Anti-CD19 Chimeric Antigen Receptors"
Charles B. Shoemaker (Tufts University)
December 14, 2012 (Friday) 10:00-11:00 a.m., Bldg. 33 Room 1N09, NIAID, Bethesda
"A general platform for rapid development of simple recombinant antitoxin products" (sponsored by NIAID)
Seminars in 2011
Peter D. Kwong (NIAID)
January 28, 2011 (Friday) 10-11 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Identification, characterization, and elicitation of broadly neutralizing antibodies that target the CD4-binding site of HIV-1"
Christopher C. Broder (Uniformed Services University)
February 25, 2011 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"A Cross-Reactive Human Monoclonal Antibody Therapeutic for Hendra Virus and Nipah Virus"
Ira Pastan (NCI)
March 25, 2011 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Recombinant Immunotoxin Treatment of Cancer"
Seth Pincus (The Research Institute for Children, New Orleans)
April 21, 2011 (Thursday) 12:30-1:30 p.m., Bldg. 37 5th Floor Conference Room, NCI, Bethesda
“Quantitative confocal microscopy defines mechanisms of intracellular neutralization of protein toxins by antibody”
Debbie Hodge (NCI)
April 22, 2011 (Friday) 10:15-11:15 a.m., Bldg. 549 Executive Board Room, NCI, Frederick
“Chronic Interferon-gamma expression - impact on B cells and autoimmunity”
Martin F Flajnik (University of Maryland School of Medicine)
May 27, 2011 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"The emergence and evolution of single-domain V regions"
Syd Johnson (MacroGenics, Inc.)
September 23, 2011 (Friday) 10:15-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Optimized bispecific antibody fragments for oncology and autoimmunity"
Seminars in 2010
Christoph Rader (NCI)
May 5, 2010 (Friday) 11 a.m.-12:15 p.m., Bldg. 37 Rooms 4041/4107, NCI, Bethesda
"Monoclonal antibody drug and target discovery in chronic lymphocytic leukemia“
Richard A. Morgan (NCI)
June 4, 2010 (Friday) 11 a.m.-12:15 p.m., Bldg. 37 Rooms 4041/4107, NCI, Bethesda
"Turning antibodies into T cell receptors“
Paul Winfield (NIAMS)
June 25, 2010 (Friday) 10-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Structural studies on the HIV-1 Rev protein”
Wei Jin Wu (FDA)
July 23, 2010 (Friday) 10-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"The roles of IGFBPs: a novel mechanism of action for trastuzumab-mediated cell growth inhibition”
Dimiter S Dimitrov (NCI)
August 27, 2010 (Friday) 10-11:15 a.m., Bldg. 549 Executive Board Room, NCI, Frederick
"Engineered antibody domains as candidate therapeutics”
Edward A Berger (NIAID)
September 24, 2010 (Friday) 10-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Masking and Unmasking HIV Neutralizing Epitopes: from Implications to Applications”
Manuel Baca (MedImmune, Inc.)
October 22, 2010 (Friday) 10-11:15 a.m., Bldg. 37 Rooms 2041/2107, NCI, Bethesda
"Beyond Antibodies: Challenges and Opportunities for Alternative Scaffold Protein Drugs”